Skandinaviska Enskilda Banken AB publ Buys 160,128 Shares of KalVista Pharmaceuticals, Inc. $KALV

Skandinaviska Enskilda Banken AB publ boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 391.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 200,991 shares of the specialty pharmaceutical company’s stock after acquiring an additional 160,128 shares during the period. Skandinaviska Enskilda Banken AB publ owned 0.40% of KalVista Pharmaceuticals worth $2,449,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the last quarter. Wolverine Asset Management LLC purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter worth about $57,000. KLP Kapitalforvaltning AS bought a new position in KalVista Pharmaceuticals during the third quarter valued at approximately $63,000. Virtus Investment Advisers LLC bought a new position in KalVista Pharmaceuticals during the second quarter valued at approximately $81,000. Finally, Tower Research Capital LLC TRC grew its holdings in KalVista Pharmaceuticals by 816.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock valued at $91,000 after buying an additional 7,180 shares in the last quarter.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $15.83 on Friday. The firm has a market capitalization of $800.14 million, a PE ratio of -4.01 and a beta of -0.19. The stock’s fifty day moving average is $15.50 and its 200 day moving average is $13.88. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.23 and a fifty-two week high of $19.00. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22.

Insider Activity at KalVista Pharmaceuticals

In other news, CFO Brian Piekos sold 4,471 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $60,134.95. Following the sale, the chief financial officer directly owned 10,529 shares in the company, valued at approximately $141,615.05. This represents a 29.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 10,940 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $147,143.00. Following the sale, the chief executive officer directly owned 416,189 shares of the company’s stock, valued at $5,597,742.05. This represents a 2.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 33,556 shares of company stock worth $484,606. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. HC Wainwright boosted their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Needham & Company LLC upped their price target on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.40.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.